Elephas, an oncology-focused diagnostics platform, raised $55 million in Series C funding, bringing its total raise to $116.5 million. The platform aims to predict a patient’s response to immunotherapy using metabolic imaging and analyzing a tumor’s architecture via a patient biopsy. This approach to immunotherapy is a therapeutic approach that helps the immune system fight cancer. The company’s platform holds promise to address the unmet need in predicting response to immunotherapy. The market snapshot shows that immunotherapy is used to treat various types of cancers, and other companies like GE Healthcare are also using emerging technologies in the fight against cancer, including theranostics – an emerging technology that fuses imaging technology with therapeutic agents to target cancer cells for destruction.
Source link
Live tumor imaging company Elephas garners $55M
